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WHEN Lacassagne (1939) first reported the induction of tumours in mice
following repeated injections of testosterone, controversy arose as to the cause of
these malignant lesions. Burrows (1945) was among the first to suggest the possi-
bility that androgens might be converted into oestrogen within the body. The
biochemical studies of Baggett, Engels, Savard and Dorfman (1956) have
demonstrated that under certain conditions this conversion does occur and several
workers (Kirkman, 1956; Rudali, Desormeaux and Juliard, 1956; Homburger,
Borges and Tregier, 1957) have reported the induction of neoplasia in rodents
treated with testosterone.
The purpose of this communication is to report the induction of tumours in
the albino rat and the golden hamster following prolonged administration of the
male sex hormone, and also to discuss and correlate these findings with the object
of helping to elucidate this problem.
MATERIAL AND METHODS
Young albino rats of undeterminate ancestry bred in this Institute were
used exclusively in these experiments. Twenty female rats at the age of 3 days
received a weekly subcutaneous injection of 0-5 mg. of testosterone propionate
in arachis oil. At 21 days the dose was gradually increased to 1 mg. and after
6 months all the survivors were receiving a weekly dose of 2-5 mg. of the male
sex hormone. The injections were continued for 21 months.
In another experiment 10 male golden hamsters when 2 weeks old received a
similar weekly subcutaneous dose of testosterone propionate. After 16 months
all the surviving hamsters were sacrificed and tissues for histological examination
were fixed either in aqueous or alcoholic Bouin prior to staining with haematoxylin
and eosm.
OBSERVATIONS
Nine rats out ofthe 20 receiving weekly inoculations oftestosterone propionate
died within the first 6 months' period of treatment. One likewise died during
the eighth month. Between 6 to 8 months after treatment with the male sex
hormone all the surviving rats began to develop an hypertrophy of the clitoris
which by the end of 12 months had become very pronounced (Fig. 1).
Out ofthe 10 rats which survived aperiod of 16 months' continuous treatment,
one developed a large palpable abdominal lesion. Two months later this animal
was killed and at autopsy it was found to possess a large unilateral ovarian
tumour. There was no evidence of any secondary growths. The remainingCARCINOGENIC ACTION OF ANDROGENS
ovary was cystic, and the left uterine horn was enlarged and congested. After
20 months testosterone treatment a second rat also developed a small abdominal
palpable lesion. At post mortem this was found to be another small unilateral
ovarian lesion. The remaining ovary appeared normal but the uterus was both
cystic and congested. Twenty-one months after commencement of testosterone
administration all the remaining rats were sacrificed and a third small unilateral
ovarian lesion was detected. Of the remaining 7 rats, all but 2 of them, had
congested uteri, and 2 possessed cystic ovaries. The pituitary glands were
macroscopically normal in both size and appearance. It was of interest to note
that no tumours developed at or near the site of inoculation.
Histological examination ofthese ovarian lesions showed them to be theca-cell
tumours. They possessed all the usual distinctive morphological features of
thecomas, and were unilateral, encapsulated and of a firm consistency. Micro-
scopically, they consisted of bundles of broad irregular shaped spindle-cells.
Mitotic figures were frequent and many binucleated cells were present (Fig. 4).
The first tumour examined had the character of a spindle-cell sarcoma, but when
grafted subcutaneously into 10 adult female albino rats, the tumour in every
instance failed to grow. The remaining two tumours were not transplanted.
The cystic ovaries contained a haemorrhagic fluid and the cells lining the cysts
appeared to have been derived from the theca interna. The uteri showed evidence
of endometrial hyperplasia which was invariably accompanied by an overgrowth
of the fibro-muscular stroma. One rat had a cystic glandular hyperplasia of the
endometrium similar to that seen in rodents following prolonged oestrogenic
administration.- In some uteri, the glands possessed proliferating epithelium
which in some instances showedatypicalformation (Fig. 3). Noneoftheseuterine
lesions could be diagnosed as malignant. There were no marked lesions in the
cervix beyond a pronounced squamous metaplasia in the region of the isthmus
seen in 2 rats. No theca-cell tumours have been recorded in any untreated albino
rats belonging to this colony.
Ofthe 2 adrenalcorticaltumours seeninthemalehamstersfollowingcontinuous
treatment with testosterone propionate, one was a large carcinoma, and the other
was a cortical adenoma. The carcinoma was large, vascular and showed evidence
of central necrosis and in some areas there was a varying degree of anaplasia
(Fig. 2). This tumour was well circumscribed and devoid of metastases. The
second tumour was a very much smaller lesion, similar in its histological structure
to the cortical lesions reported by Horning and Whittick (1954) in the adrenals of
hamsters following prolonged administration of stilboestrol. No spontaneous
adrenal tumours have been observed in the colony ofoldhamsters in this Institute.
It was ofinterest to note that in both the rat and the hamster after prolonged
treatment with the male sex hormone, the pituitary glands were normal in size
and appearance. In all instances there appeared to be an abnormal number of
acidophils in the anterior hypophysis.
DISCUSSION
Both experimental and clinical evidence supports the contention that
androgens, under certain conditions, act as non-specific carcinogens. Burrows
(1945) when endeavouring to interpret the results of earlier investigators, was one
of the first to suggest that the occasional development of tumours following
androgen administration, might be due to its conversion within the body into
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oestrogen. He pointed out that oestrogen is a metabolic product of androgen,
perhaps in the form of ostrone. An earlier observation recorded by Parkes (1935)
is of particular interest in this respect. He found that androstanediol provokes
vaginal cornification in normal but not in spayed rats, a fact which suggests that
in this instance the ovary may play a role in the conversion of an androgen into
an oestrogen. Later Steinach, Kun and Peczenik (1936) found that the admini-
stration ofandrosterone to rats was followed by an increased excretion ofoestrogen
in the urine. Steinach and Kun (1937) reported similar results in man following
treatment with either androsterone or testosterone propionate. Observations
of a similar nature were reported by Callow and Callow (1938) and Foss (1939).
An increased output in urinary oestrogen after treatment of human ennchoids
with androgen has been recorded by Hamilton, Dorfman and Hubert (1941),
and in dogs by Paschkis, Cantarow and Raskoff (1943). Also gynaecomastia
has been reported by McCullogh and Rossmiller (1941) following the administration
of androgen to men, and Nathanson and Kelly (1952) recorded an increase of
oestrogen in patients with breast cancer treated with androgens. Recently
Myers et al. (1956) conclude that testosterone treatment induces objective
suppression of growth in 20 to 25 per cent of women with breast cancer. Hence
about halfof those who might be expected to respond to the male sex hormone on
the basis of oestrogen antagonism fail to do so. They also point out that failure
to respond to therapy usually involves marked acceleration of the disease. From
these and other clinical observations they contend that androgen may cause
exacerbation ofbreast cancer, and that conversion to oestrogen affords a reasonable
explanation. It is also suggested, however, that the breast cancer cell, being
abnormal in so many respects to normal cells, may have lost its ability to distinguish
between androgen and oestrogen, and, if such is the case, the malignant cell might
thrive on any gonadal steroid. The interest of this speculation lies in the fact
that many experimentally induced hormone-dependent tumours in rodents are
dependent on either androgen or oestrogen for their sustained growth as transplants
in host animals (Gardner, 1954; Muhlboch, 1953; Kirkman, 1956).
Lacassagne (1939) was the first to report the actual induction of tumours
in mice following treatment with androgens. Thirty-seven per cent of his mice
treated with testosterone propionate or testosterone acetate developed sub-
cutaneous sarcomas. According to Burrows (1952) injections of oil alone in
rats occasionally induce a low percentage of sarcomas, but this is not the case in
mice. In view of the high percentage of mice which developed neoplasia there
seems little doubt that tumorigenesis was in this instance associated with a
possible conversion of androgen into an oestrogen. This earlier work of
EXPLANATION OF PLATE
Fi.. I.-Hypertrophy of the clitoris in a 12-months-old rat which had received regular doses
of testosterone propionate since the 3rd day after birth. x 1-8.
FIG. 2.-Carcinoma of the adrenal gland in a rat which had received regular treatment with
testosterone propionate for approximately 16 months. Observe evidence of central
necrosis. x 4.
Fie. 3.-Uterine glands of an adult Albino rat following treatment with testosterone propionate
since 3 days old. x 72.
FiG. 4.-Theca-cell ovarian tumour in an Albino rat which developed after 16 months'
treatment with the male sex hormone. x 90.
416Vol. XII, No. 3. BRITISH JOURNAL OF CANCER.
I
2
4
Horning.
3CARCINOGENIC ACTION OF ANDROGENS
Lacassagne, is supported by the recent experiments of Kirkman (1956), Rudali,
Desmoreaux and Juliard (1956), Homburger, Borges and Tregier (1957). The
studies of Kirkman (1956) in the Syrian hamster are of special interest. Instead
of using the male sex hormone in a suspension of oil, he implanted pellets of
testosterone propionate subcutaneously. Out of a total of 64 hamsters of both
sexes, some of which were gonadectomised, 46 developed tumours. No tumours
developed at the site ofimplantation. Thirty-five were adrenal cortical adenomas
and one was a theca-cell ovarian tumour. The average latent period ofinduction
was nearly 2 years. Rudali et at. (1956) have succeeded in inducing kidney
neoplasia in AKR male mice following continuous treatment with androgen for
19 months. More recently Homburger et al. (1957) have obtained uterine
sarcomas in the Swiss and BALB strains with testosterone treatment. These
results, and those already described in this communication on the induction of
theca-cell ovarian tumours in the rat following continuous administration with
testosterone shortly after birth, together with the adrenal cortical tumours in the
hamster after similar treatment, are also in accord with the early observations
of Lacassagne and those of recent workers.
The author agrees with Kirkman (1956) in assuming that testosterone under
certain conditions acts as a non-specific carcinogen. Tumours which arise in
animals following androgen administration appear to have a much longerperiod of
induction than similar lesions resulting from oestrogenic stimulation. Thus
some of the adrenal tumours induced by Kirkman (19056) in the male hamster
with testosterone did not appear until 900 days after commencement oftreatment.
Also the theca-cell ovarian tumours in the hamster also induced by Kirkman in
the same series of experiments took 693 days to develop, which is approximately
the same period of induction as the theca-cell ovarian tumours in the rat. This
long latent period before the onset of tumorigenesis by androgens may be due to
the fact that the mechanism of its conversion into an oestrogen is a slow process.
New light has been shed on this mechanism by the recent biochemical studies
of Heard et al. (1955) and Bagget et al.- (1956). The former investigators have
found the excretion of C14 labelled oestrone by a pregnant mare to which C14
labelled testosterone had been administered, while Bagget etal. have conclusively
demonstrated the conversion oftestosterone tooestradial byhuman ovarian tissue.
Although the mechanism of this phenomenon is not yet fully understood, a
possible conversion of testosterone to oestrogenic steroids offers an interesting
explanation of some of the experimental and clinical results discussed in this
paper.
SUMMARY
1. The induction of theca-cell ovarian tumours in the Albino rat, together
with adrenal corticallesions in thegolden hamster are reportedfollowingprolonged
administration of testosterone.
2. Literature on the development ofneoplasia after treatment with androgens
has been reviewed in the light of recent biochemical evidence which suggests a
possible conversion of testosterone to oestrogenic steroids.
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